77 results on '"Gatzemeier, Ulrich"'
Search Results
2. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
3. Lung Toxicity of Chemotherapeutic Agents
4. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial
5. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
6. Long-Term Safety and Tolerability of Sorafenib in Patients with Advanced Non–Small-Cell Lung Cancer: A Case-Based Review
7. Efficacy and safety of bronchoscopic laser therapy in patients with tracheal and bronchial obstruction: a retrospective single institution report
8. Characteristics, treatment patterns and outcomes of patients with small cell lung cancer—A retrospective single institution analysis
9. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
10. Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – A retrospective single institution analysis
11. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study
12. Thalidomide in lung cancer therapy—what have we learned?
13. Vorwort
14. Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer
15. XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
16. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
17. Multicenter Randomized Open-Label Phase III Study Comparing Efficacy, Safety, and Tolerability of Conventional Carboplatin Plus Etoposide Versus Dose-Intensified Carboplatin Plus Etoposide Plus Lenograstim in Small-Cell Lung Cancer in “Extensive Disease” Stage
18. Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s Lymphoma
19. Vorwort
20. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
21. A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
22. Phase III Trial Comparing Carboplatin, Paclitaxel, and Bexarotene With Carboplatin and Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: SPIRIT II
23. Diagnostics and staging procedures in non-small cell lung cancer - is less more?
24. Comment and Reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective
25. Vorwort
26. Title Page / Table of Contents
27. Nichtkleinzelliges Lungenkarzinom – Diagnostik und stadienadaptierte Therapie
28. Okkulte Fremdkörperaspiration als Differentialdiagnose zum Bronchialka
29. P1-209: Surgery and radiotherapy versus radiotherapy in patients with small-cell lung cancer (SCLC) responding to chemotherapy with paclitaxel, etoposide phosphate, and carboplatin (TEC) - analysis of a randomized phase- II-trial
30. C6-01: Correlations of biomarker expression and clinical outcome in a large phase III trial of pemetrexed plus cisplatin or gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
31. P3-084: Second-line treatment of Non-Small Cell Lung Cancer (NSCLC) with erlotinib is potentially cost-saving for the German healthcare system
32. E03-01: New cytotoxics
33. P3-134: Sunitinib in combination with gemcitabine plus cisplatin for advanced non–small cell lung cancer (NSCLC): preliminary results from a phase I dose escalation study
34. P2-328: Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC)
35. B1-03: Phase II double blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC)
36. C5-03: Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP)
37. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
38. A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective
39. Oral Vinorelbine in the Treatment of Non-Small Cell Lung Cancer
40. Gefitinib Monotherapy in Chemotherapy-Naive Patients with Inoperable Stage III/IV Non-Small-Cell Lung Cancer
41. Vorwort
42. «Pillnitzer interdisziplinäres Gespräch» – Zusammenfassung
43. Randomized Multicenter Phase II Study of Gemcitabine Versus Docetaxel as First-Line Therapy with Second-Line Crossover in Advanced-Stage Non–Small-Cell Lung Cancer
44. Benefit in lung function improvement and side-effect profile of long-term responders: An analysis of 14 NSCLC patients treated for at least 9 months with gefitinib
45. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen
46. A Pilot Trial of Gefitinib in Combination with Docetaxel in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
47. Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18
48. Pemetrexed–cisplatin combination in mesothelioma
49. Gefitinib (‘Iressa’): a new therapy for advanced non-small-cell lung cancer
50. Phase III Study of Matrix Metalloproteinase Inhibitor Prinomastat in Non–Small-Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.